Psychedelics are experiencing a resurgence of interest as scientific, pharmaceutical, and mental health communities revisit their therapeutic potential. The newest entrant to the hallucinogenic landscape is Field Trip (CSE: FTRP) (OTCQB: FTRP), an American-based company that has recently announced it will partner with the Dutch firm Entheon to conduct pharmacology research into DMT, a compound found naturally in plants and animals as well as produced endogenously by our brains. Go here
Known as the “spirit molecule”, DMT can be inhaled for a short psychedelic experience or mixed with monoamine oxidase inhibitor (MAOI) herbs to form an ayahuasca brew that can last hours. During this time, users often report encountering elf-like entities and having meaningful spiritual experiences.
DMT is a powerfully hallucinogenic compound that acts by flooding sigma-1 receptors, which are involved in regulating emotional responses. It is thought that this may lead to a dissolution of top-down cortical control over medial temporal lobe activity, allowing for the expression of psychedelic effects like intense hallucinations and spiritual experiences.
In Canada, DMT is illegal to possess or trade unless you have a Section 56 exemption from Health Canada. Section 56 allows for the supervised use of psychedelics for medical or scientific research and in the public interest, but this is difficult to obtain. Many Canadian universities have active psychedelic research departments, and several therapy clinics offer Section 56-based psychedelic psychotherapy sessions, in which you pay for your session, and are given the drugs free of charge as part of your participation in research.